US FDA pauses new enrollment in Biohaven's epilepsy drug trials

Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of ​its experimental epilepsy drug after rodent findings, sending its ‌shares down ...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。